Hae Yong Yoo

Prof. Dr. Hae Yong Yoo


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
SCSeung Ho Choi
Seung Ho Choi
HYHeekyoung Yang
Heekyoung Yang
SLSeung Ho Lee
Seung Ho Lee
JKJoo-Hyun Ki
Joo-Hyun Ki
DNDo-Hyun Nam
Do-Hyun Nam
HYHae Yong Yoo
Hae Yong Yoo
Radiation therapy is one of the most effective therapeutic tools for brain metastasis. However, it is inevitable that some cancer cells become resistant to radiation. This study is focused on the identification of genes associated with radioresistance in metastatic brain tumor from lung cancer and the functional examination of the selected genes with regards to altered sensitivity of cancer cells to radiation. After establishing radioresistant cells from the xenograft model, we explored the significant transcriptional changes by performing DNA microarray profiling. Functional analyses in vitro and in vivo performed to validate the gene responsible for radioresistance. Transcriptional changes induced by radiation therapy are much more extensive in H460 cells than in PC14PE6 cells. The expression levels of TopBP1 and Claspin were increased in the cancer cells that survived radiation therapy. Depletion of TopBP1 or Claspin using shRNA showed an enhancement of sensitivity to radiation in radioresistant lung cancer cells (PC14PE6). Moreover, increased levels of TopBP1 or Claspin endowed cells a higher resistance to radiation. In xenograft models, the knock-down of TopBP1 or Claspin significantly prolonged the median survival time post radiation therapy. We analyzed the gene expression profiles of the radiosensitive cells and the radioresistant cells to define a set of genes that may be involved in endowing lung cancer cells radioresistance post brain metastasis. Functional analyses indicated that the expression TopBP1 and Claspin positively affects the survival of cancer cells and thus negatively the xenograft metastasis model animals in response to radiation. These results show that TopBP1 and Claspin can be potential targets for the enhanced efficacy of radiotherapy.

31 March 2015 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
HYHeejei Yoon
Heejei Yoon
SPSanghui Park
Sanghui Park
HJHyunjeong Ju
Hyunjeong Ju
SHSang Yun Ha
Sang Yun Ha
ISInSuk Sohn
InSuk Sohn
YKYoung Hyeh Ko
Young Hyeh Ko

24 September 2015 in Haematologica
Verified
Journal Article
Open access
PDF file
SLS. H. Lee
S. H. Lee
JKJ. S. Kim
J. S. Kim
JKJ. Kim
J. Kim
SKS. J. Kim
S. J. Kim
WKW. S. Kim
W. S. Kim
HYHae Yong Yoo
Hae Yong Yoo
Angioimmunoblastic T-cell lymphoma (AITL) is a rare, aggressive type of T-cell lymphoma (TCL) that accounts for 18.5% of mature T-cell or natural killer (NK)-cell lymphomas.[1][1] Mutations in the IDH2, TET2 , and DNMT3A genes, frequently seen in various types of cancer, have also been linked to

19 January 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JKJin Hyun Kang
Jin Hyun Kang
SLSeung Ho Lee
Seung Ho Lee
JLJawon Lee
Jawon Lee
MCMurim Choi
Murim Choi
JCJunhun Cho
Junhun Cho
HYHae Yong Yoo
Hae Yong Yoo
Background: BCOR acts as a corepressor of BCL6, a potent oncogenic protein in cancers of the lymphoid lineage. We have found the recurrent somatic mutation of BCOR occurred in mature T-cell lymphoma (TCL). The role of BCOR mutation in lymphoid malignancies is unknown.Methods: Lymphoma patient samples were analyzed to identify missense mutations in BCOR using Sanger sequencing. Transfection, RNA interference, immunoprecipitation, western blotting, cell proliferation, cytokine assays and quantitative real-time PCR were employed to determine the functional relevance of the novel K607E mutation in BCOR. The significant transcriptional changes were analyzed by performing DNA microarray profiling in cells expressing BCOR K607E mutant.Results: One hundred thirty-seven lymphoma patient samples were analyzed to identify K607E mutation of the BCOR gene. The BCOR K607E mutation was identified in 15 of 47 NK/T cell lymphoma cases (31.9%), 2 of 18 angioimmunoblastic T-cell lymphoma cases (11.1%), 10 of 30 peripheral T-cell lymphoma, not otherwise specified cases (33.3%), and 13 of 42 diffuse large B-cell lymphoma cases (30.9%). Molecular analysis of BCOR K607E mutation revealed that compared to the wild-type BCOR, the mutant BCOR bound to the BCL6, PCGF1, and RING1B proteins with lesser affinity. Ectopic expression of BCOR K607E mutant significantly enhanced cell proliferation, AKT phosphorylation and the expression of interleukin-2 (IL-2) with up-regulated expression ofHOXand S100 protein genes in T cells. BCOR silencing also significantly enhanced cell proliferation, AKT phosphorylation, and IL-2 production.Conclusions: Functional analyses indicated that K607E mutation of BCOR is oncogenic in nature and can serve as a genetic marker of T-cell lymphoma.

1 February 2022 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
SCSeung Ho Choi
Seung Ho Choi
KCKyoungjoo Cho
Kyoungjoo Cho
EKEun Seon Kim
Eun Seon Kim
HYHae Yong Yoo
Hae Yong Yoo

1 June 2015
Verified
Journal Article
Closed access
DLDo Hyoung Lim
Do Hyoung Lim
WKWon Seog Kim
Won Seog Kim
SKSeok Jin Kim
Seok Jin Kim
HYHae Yong Yoo
Hae Yong Yoo
YKYoung Hyeh Ko
Young Hyeh Ko